Financials data is unavailable for this security.
View more
Year on year BioCryst Pharmaceuticals Inc grew revenues 22.37% from 270.83m to 331.41m while net income improved from a loss of 247.12m to a smaller loss of 226.54m.
Gross margin | 98.06% |
---|---|
Net profit margin | -30.01% |
Operating margin | -9.87% |
Return on assets | -24.42% |
---|---|
Return on equity | -- |
Return on investment | -32.17% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at BioCryst Pharmaceuticals Inc fell by 193.79m. Cash Flow from Financing totalled 32.49m or 9.80% of revenues. In addition the company used 95.14m for operations while cash used for investing totalled 131.50m.
Cash flow per share | -0.595 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -2.26 |
---|---|
Tangible book value per share | -2.26 |
More ▼
Balance sheet in USDView more
Current ratio | 2.78 |
---|---|
Quick ratio | 2.73 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 2.29 |
More ▼